Covid 19: Winter Plan Debate

Full Debate: Read Full Debate
Department: Leader of the House
Tuesday 24th November 2020

(3 years, 5 months ago)

Lords Chamber
Read Full debate Read Hansard Text Read Debate Ministerial Extracts
Baroness Evans of Bowes Park Portrait Baroness Evans of Bowes Park (Con)
- Hansard - - - Excerpts

We have a central government unit that will be working on this, but also DCMS is working very closely with social media platforms to help identify false claims, exactly as the noble Lord said, about both the virus and the vaccine and, where necessary, promoting authoritative sources of information in their place. I assure the noble Lord that we are very cognisant of these issues and are working hard to make sure that the rollout of the national vaccination plan is accompanied by a public health strategy and message to make sure that people understand that we will always put the safety of the public first, and that any vaccine that is approved will have gone through an incredibly rigorous process to pass that hurdle, as the noble Lord will well know.

Baroness Rawlings Portrait Baroness Rawlings (Con) [V]
- Hansard - -

My Lords, it is very encouraging news that vaccines will be available in 2021—a remarkable feat. We should all congratulate Oxford, which is not only supplying 100 million vaccines to our Government but is doing so on a not-for-profit basis. Is Pfizer, the supplier of the first vaccine to be announced, which is supplying us with 40 million doses, doing so on the same basis? More importantly, deal or no deal, as the Pfizer vaccine is, I believe, coming from Belgium, will there be import duties or tariffs?

Baroness Evans of Bowes Park Portrait Baroness Evans of Bowes Park (Con)
- Hansard - - - Excerpts

Well, we have secured more than 40 million doses of the Pfizer vaccine, as my noble friend rightly said, which is enough for about a third of our population, and in total we have secured early access to more than 355 million doses through a portfolio of promising new vaccines—so we are very well placed to take advantage of both the Pfizer and Oxford vaccines, which have now reached the stages they have, and other vaccines that will hopefully follow through on the back of their success.